The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist

Author(s): Stuart Bailey , Roger Palframan , Gillian Watt , John Porter .

Journal Name: Current Immunology Reviews

Volume 8 , Issue 2 , 2012

Become EABM
Become Reviewer

Abstract:

Blocking the action of alpha4 integrin would be expected to be of therapeutic benefit in the management of autoimmune diseases. Although this has been successfully demonstrated in the clinic with a monoclonal antibody for the treatment of multiple sclerosis, there are no small molecule alpha4 integrin antagonists on the market despite significant endeavour over the last 15-20 years. We review our efforts in this area, starting from a cyclic peptide based on an integrin recognition sequence and culminating in the low molecular weight clinical candidate, CDP323. We include a discussion on pre-clinical pharmacological data for CDP323.

Keywords: Alpha4 integrin, CDP323, integrin antagonists, VLA-4 integrin

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2012
Page: [135 - 140]
Pages: 6
DOI: 10.2174/157339512800099675
Price: $58

Article Metrics

PDF: 4